MZ SR in line with strengthening priorities the competence status of general practitioners as of 1.2. 2023 has been released by the prescribing and indication restrictions for oral lipid lowering agents. The general physician may thus perform comprehensive patient management with dyslipidaemias in their practice without the need to be sent to a doctor specialist.
|
ATC / active substance: |
C10AA05 / Atorvastatin C10AA07 / Rosuvastatin C10AX09 / Ezetimibe C10BA02 / Simvastatin and ezetimibe C10BA05 / Atorvastatin and ezetimibe C10BA05 / Rosuvastatin and ezetimibe |
|
Reference group: |
C10AA05 / Atorvastatin PO 40 mg C10AA05 / Atorvastatin p.o C10AA05 / Atorvastatin p.o. 80 mg C10AA07 / Rosuvastatin 10 mg C10AA07 / Rosuvastatin p.o 15 mg C10AA07 / Rosuvastatin 20 mg C10AA07 / Rosuvastatin 30 mg C10AA07 / Rosuvastatin 40 mg C10AX09 / Ezetimibe 10 mg C10BA02 / Simvastatin and ezetimibe p.o. 10/20 mg C10BA02 / Simvastatin and ezetimibe p.o. 10/40 mg C10BA05 / Atorvastatin and ezetimibe p.o. 10/10 mg C10BA05 / Atorvastatin and ezetimibe p.o. 10/20 mg C10BA05 / Atorvastatin and ezetimibe p.o. 10/40 mg C10BA05 / Atorvastatin and ezetimibe p.o. 10/80 mg C10BA05 / Rosuvastatin and ezetimibe p.o. 5/10 mg C10BA05 / Rosuvastatin and ezetimibe p.o. 10/10 mg C10BA05 / Rosuvastatin and ezetimibe p.o. 20/10 mg C10BA05 / Rosuvastatin and ezetimibe PO 40/10 mg |